B‐cell Therapy for Multiple Sclerosis: Entering an era
Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disa...
Gespeichert in:
| Veröffentlicht in: | Annals of neurology 2018-01, Vol.83 (1), p.13-26 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 26 |
|---|---|
| container_issue | 1 |
| container_start_page | 13 |
| container_title | Annals of neurology |
| container_volume | 83 |
| creator | Greenfield, Ariele L. Hauser, Stephen L. |
| description | Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B‐cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, has led to major progress in deciphering the immune pathogenesis of MS. Here, we review the nuanced roles of B cells in MS autoimmunity, the clinical data supporting use of ocrelizumab and other anti‐CD20 therapies in the treatment of MS, as well as safety and practical considerations for prescribing. Last, we summarize remaining unanswered questions regarding the proper role of anti‐CD20 therapy in MS, its limitations, and the future landscape of B‐cell‐based approaches to treatment. Ann Neurol 2018;83:13–26 |
| doi_str_mv | 10.1002/ana.25119 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5876115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1977780650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5099-93635fff7d07bab4f403ef7bf085842f78ea52e1777bbf8879d7176333bb71893</originalsourceid><addsrcrecordid>eNp10b1OwzAUBWALgWgpDLwAisQCQ-A6tmObAalU5UcqMFBmy0ntNihNit2AuvEIPCNPgqFQARKTB386vr4HoV0MRxggOdaVPkoYxnINtTEjOBYJleuoDSSlMcOEttCW9w8AIFMMm6iVyITShEIbibO3l9fclGU0nBinZ4vI1i66bsp5MStNdJeXxtW-8CdRv5obV1TjSFdRkNtow-rSm52vs4Puz_vD3mU8uL246nUHcc5AyliSlDBrLR8Bz3RGLQViLM8sCCZoYrkwmiUGc86zzArB5YhjnhJCsoxjIUkHnS5zZ002NaPcVHOnSzVzxVS7hap1oX7fVMVEjesnxQRPcdhGBx18Bbj6sTF-rqaF__ixrkzdeIVleFtAyiDQ_T_0oW5cFb4XlATGqRAkqMOlysNmvDN2NQwG9dGHCn2ozz6C3fs5_Up-FxDA8RI8F6VZ_J-kujfdZeQ7fsyTtA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1990574883</pqid></control><display><type>article</type><title>B‐cell Therapy for Multiple Sclerosis: Entering an era</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Greenfield, Ariele L. ; Hauser, Stephen L.</creator><creatorcontrib>Greenfield, Ariele L. ; Hauser, Stephen L.</creatorcontrib><description>Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B‐cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, has led to major progress in deciphering the immune pathogenesis of MS. Here, we review the nuanced roles of B cells in MS autoimmunity, the clinical data supporting use of ocrelizumab and other anti‐CD20 therapies in the treatment of MS, as well as safety and practical considerations for prescribing. Last, we summarize remaining unanswered questions regarding the proper role of anti‐CD20 therapy in MS, its limitations, and the future landscape of B‐cell‐based approaches to treatment. Ann Neurol 2018;83:13–26</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.25119</identifier><identifier>PMID: 29244240</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antigens, CD20 - metabolism ; Autoimmunity ; B-Lymphocytes - immunology ; CD20 antigen ; Cell- and Tissue-Based Therapy ; Clinical Trials as Topic ; Humans ; Humoral immunity ; Immunity ; Immunotherapy - methods ; Lymphocytes B ; Medical treatment ; Monoclonal antibodies ; Multiple sclerosis ; Multiple Sclerosis - pathology ; Multiple Sclerosis - therapy ; Pathogenesis ; Patients ; Therapy</subject><ispartof>Annals of neurology, 2018-01, Vol.83 (1), p.13-26</ispartof><rights>2017 American Neurological Association</rights><rights>2017 American Neurological Association.</rights><rights>2018 American Neurological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5099-93635fff7d07bab4f403ef7bf085842f78ea52e1777bbf8879d7176333bb71893</citedby><cites>FETCH-LOGICAL-c5099-93635fff7d07bab4f403ef7bf085842f78ea52e1777bbf8879d7176333bb71893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.25119$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.25119$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29244240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greenfield, Ariele L.</creatorcontrib><creatorcontrib>Hauser, Stephen L.</creatorcontrib><title>B‐cell Therapy for Multiple Sclerosis: Entering an era</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B‐cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, has led to major progress in deciphering the immune pathogenesis of MS. Here, we review the nuanced roles of B cells in MS autoimmunity, the clinical data supporting use of ocrelizumab and other anti‐CD20 therapies in the treatment of MS, as well as safety and practical considerations for prescribing. Last, we summarize remaining unanswered questions regarding the proper role of anti‐CD20 therapy in MS, its limitations, and the future landscape of B‐cell‐based approaches to treatment. Ann Neurol 2018;83:13–26</description><subject>Antigens, CD20 - metabolism</subject><subject>Autoimmunity</subject><subject>B-Lymphocytes - immunology</subject><subject>CD20 antigen</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Humoral immunity</subject><subject>Immunity</subject><subject>Immunotherapy - methods</subject><subject>Lymphocytes B</subject><subject>Medical treatment</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - pathology</subject><subject>Multiple Sclerosis - therapy</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Therapy</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10b1OwzAUBWALgWgpDLwAisQCQ-A6tmObAalU5UcqMFBmy0ntNihNit2AuvEIPCNPgqFQARKTB386vr4HoV0MRxggOdaVPkoYxnINtTEjOBYJleuoDSSlMcOEttCW9w8AIFMMm6iVyITShEIbibO3l9fclGU0nBinZ4vI1i66bsp5MStNdJeXxtW-8CdRv5obV1TjSFdRkNtow-rSm52vs4Puz_vD3mU8uL246nUHcc5AyliSlDBrLR8Bz3RGLQViLM8sCCZoYrkwmiUGc86zzArB5YhjnhJCsoxjIUkHnS5zZ002NaPcVHOnSzVzxVS7hap1oX7fVMVEjesnxQRPcdhGBx18Bbj6sTF-rqaF__ixrkzdeIVleFtAyiDQ_T_0oW5cFb4XlATGqRAkqMOlysNmvDN2NQwG9dGHCn2ozz6C3fs5_Up-FxDA8RI8F6VZ_J-kujfdZeQ7fsyTtA</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Greenfield, Ariele L.</creator><creator>Hauser, Stephen L.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201801</creationdate><title>B‐cell Therapy for Multiple Sclerosis: Entering an era</title><author>Greenfield, Ariele L. ; Hauser, Stephen L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5099-93635fff7d07bab4f403ef7bf085842f78ea52e1777bbf8879d7176333bb71893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens, CD20 - metabolism</topic><topic>Autoimmunity</topic><topic>B-Lymphocytes - immunology</topic><topic>CD20 antigen</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Humoral immunity</topic><topic>Immunity</topic><topic>Immunotherapy - methods</topic><topic>Lymphocytes B</topic><topic>Medical treatment</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - pathology</topic><topic>Multiple Sclerosis - therapy</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greenfield, Ariele L.</creatorcontrib><creatorcontrib>Hauser, Stephen L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greenfield, Ariele L.</au><au>Hauser, Stephen L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B‐cell Therapy for Multiple Sclerosis: Entering an era</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2018-01</date><risdate>2018</risdate><volume>83</volume><issue>1</issue><spage>13</spage><epage>26</epage><pages>13-26</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><abstract>Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly effective against relapsing forms of the disease and is also the first treatment approach proven to protect against disability worsening in primary progressive MS. Moreover, evolving clinical experience with B‐cell therapy, combined with a more sophisticated understanding of humoral immunity in preclinical models and in patients with MS, has led to major progress in deciphering the immune pathogenesis of MS. Here, we review the nuanced roles of B cells in MS autoimmunity, the clinical data supporting use of ocrelizumab and other anti‐CD20 therapies in the treatment of MS, as well as safety and practical considerations for prescribing. Last, we summarize remaining unanswered questions regarding the proper role of anti‐CD20 therapy in MS, its limitations, and the future landscape of B‐cell‐based approaches to treatment. Ann Neurol 2018;83:13–26</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29244240</pmid><doi>10.1002/ana.25119</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-5134 |
| ispartof | Annals of neurology, 2018-01, Vol.83 (1), p.13-26 |
| issn | 0364-5134 1531-8249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5876115 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antigens, CD20 - metabolism Autoimmunity B-Lymphocytes - immunology CD20 antigen Cell- and Tissue-Based Therapy Clinical Trials as Topic Humans Humoral immunity Immunity Immunotherapy - methods Lymphocytes B Medical treatment Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - pathology Multiple Sclerosis - therapy Pathogenesis Patients Therapy |
| title | B‐cell Therapy for Multiple Sclerosis: Entering an era |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T03%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B%E2%80%90cell%20Therapy%20for%20Multiple%20Sclerosis:%20Entering%20an%20era&rft.jtitle=Annals%20of%20neurology&rft.au=Greenfield,%20Ariele%20L.&rft.date=2018-01&rft.volume=83&rft.issue=1&rft.spage=13&rft.epage=26&rft.pages=13-26&rft.issn=0364-5134&rft.eissn=1531-8249&rft_id=info:doi/10.1002/ana.25119&rft_dat=%3Cproquest_pubme%3E1977780650%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1990574883&rft_id=info:pmid/29244240&rfr_iscdi=true |